Skip to main content
Premium Trial:

Request an Annual Quote

Hiroyuki Mitani Named CEO of GE Healthcare Technologies, Japan; Alan Williamson Joins SAB at Genstruct, Lieu is Business Development Director; Robert Friel Appointed to Millenium Pharmaceuticals Board; and Others.

Hiroyuki Mitani has been appointed president and CEO of GE Healthcare Technologies, Japan. Mitani joined GE Japan in 1992 as director of business development. Prior to his current role, he served as general manager of marketing and sales for GE Transportation, Japan. In 1996, he served as general manager of marketing and sales for GE Energy, Japan.


Mitani received his MS in operations research from Stanford University in 1984 and an MS in mechanical engineering from the Universityof California, Berkeley, in 1983. He received his BS in mechanical engineering from the Universityof Tokyo in 1977.

Alan Williamson has joined Genstruct's scientific advisory board, the Cambridge, Mass.-based drug discovery company said today.


Williamson is a former member of the advisory council to the US National Human Genome Research Institute of the National Institutes of Health and is currently a member of the Sequencing and the HapMap Advisory Panels.


He previously served as a professor of biochemistry at the Universityof Glasgow, and has held senior research management positions at GlaxoSmithKline and Merck & Co.


Genstruct has also named Charlie Lieu as director of business development and marketing. Lieu previously served at Merck as a technology analyst and corporate liaison for Merck Research Labs and manager of technical marketing and sales for Merck subsidiary Rosetta Inpharmatics.


Lieu holds an MBA from the Sloan School of Management at the Massachusetts Institute of Technology, an MS in electrical engineering from MIT. She received her BS in computer science from Texas A&M University.


Robert Friel has joined Millennium Pharmaceuticals' board of directors and will serve on the board's audit committee, the company said this week.


Friel currently serves as executive vice president and chief financial officer of PerkinElmer. Prior to joining PerkinElmer, Friel held a variety of senior finance positions at AlliedSignal, now Honeywell International. Friel also currently serves as a member of the board of directors of Fairchild Semiconductor Corporation.


Michael Astrue and Frank Armstrong have been named to CuraGen's board of directors, the company said this week.


Astrue most recently served as the president and chief executive officer of Transkaryotic Therapies and before that served as vice president and general counsel for Biogen. Astrue also served as associate counsel to the President where he advised former US Presidents Ronald Reagan and George Herbert Walker Bush. He holds a BA in English and philosophy from YaleUniversity, and attained a JD from Harvard Law School.


Armstrong currently serves as CEO of Bioaccelerate. He also served as CEO of Provensis, and CEO of Phoqus, and held senior level positions at Bayer and Zeneca Pharmaceuticals. Armstrong holds an MB from the Royal Postgraduate Medical School of London.


David Larocca has been appointed associate director of Advanced Cell Technology, the firm's parent company ACT Holdings said this week.


Larocca will work with ACT's California office which is doing stem cell research. He previously served as associate director of research at Selective Genetics and holds a PhD in cell and molecular biology from the University of Southern California.


Daniel Kisner has resigned from the board of directors of Sequenom, according to an SEC filing dated June 15.


Kisner had served as a member the company's audit committee. Harry Hixson, one of Sequenom's independent directors will fill the vacancy on the audit committee, the company said.


G. Steven Burrill has been named to Zoomedia's board of directors, the company said this week.


Burrill is the CEO of Burrill & Co., a San Francisco-based life sciences firm. He previously held administrative positions at Ernst & Young. Burrill currently serves as chairman of the board of Icoria, Pharmasset, and Pyxis Genomics. He also serves on the board of directors of Catalyst Biosciences, DepoMed, Galapagos Genomics, Targacept, and Third Wave Technologies.


Matthew Fust will join the board of directors of Sunesis Pharmaceuticals, the company said this week. Fust currently serves as senior vice president and chief financial officer of Jazz Pharmaceuticals.


Prior to joining Jazz Pharmaceuticals in 2003, Fust was CFO of Perlegen Sciences and he held senior level administrative positions at Alza from 1996 to 2001. Fust holds an MBA from the StanfordUniversity's Graduate School of Business and a BA in accounting from the Universityof Minnesota.


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.